Immunotherapy in Shanghai Tongji Hospital, International Department

Shanghai Tongji Hospital (Shanghai Tongji Hospital), affiliated with Tongji University, is a major public tertiary hospital in Shanghai and one of China’s leading centers for hematology and blood cancer treatment, including lymphoma, leukemia, and multiple myeloma. The Hematology Department and Blood-Tumor Clinical Research Center specialize in advanced cellular immunotherapy, including CAR-T and CAR-NK therapies.

The hospital established its CAR-T program in 2014 and has since performed more than 1,500 CAR-T cell infusions, making it one of the most experienced centers in this field. Over years of clinical development, the team has built a standardized treatment pathway covering patient selection, cell preparation, bridging therapy, infusion, and long-term follow-up. Reported outcomes include a 3-month complete remission rate of approximately 87.5% in lymphoma patients.

For high-risk and refractory cases, the hospital has developed combination approaches such as CAR-T based therapies integrated with additional treatment strategies, improving long-term remission outcomes in selected patient groups. The center has also contributed to the development of innovative approaches such as epigenetic immunotherapy for patients who have not responded to multiple prior treatments.

In lymphoma care, particularly diffuse large B-cell lymphoma (DLBCL), the hospital reports high clinical effectiveness, including strong remission rates in both newly diagnosed and relapsed or refractory cases, significantly improving outcomes compared to conventional therapies.

The hospital is actively involved in global research and clinical innovation, including publications on next-generation CAR-NK cell therapies in leading scientific journals such as Nature Cancer. Its research focuses on improving accessibility, durability, and safety of cellular immunotherapy.

Patient care is organized through a multidisciplinary tumor board involving hematology, radiology, pathology, imaging, nutrition, and psychological support specialists. Advanced diagnostic tools include immunophenotyping for CAR-T eligibility, biopsy techniques, and imaging-guided assessments to ensure precise treatment planning.

Shanghai Tongji Hospital is recognized for its extensive clinical experience in CAR-T therapy, participation in clinical trials, high remission outcomes in lymphoma treatment, and contribution to international research in cellular immunotherapy.